|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this single-center prospective randomized study, patients with subacute STEMI presenting ≥12 and ≤48 h after symptom onset were randomized to primary PCI with or without manual TA in a 1:1 ratio.
|
29869443 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low risk patients identified using CADILLAC risk score with STEMI treated successfully with primary PCI have a low adverse event rate on the third day or later of hospitalization suggesting that an earlier discharge is safe in properly selected patients.
|
27896906 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
|
24952855 |
2014 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We chose the acute ST-elevation myocardial infarction (ASTEMI) patients treated with direct PCI to compare different administration routes of diltiazem.
|
30223281 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This paper presents a constructive critical appraisal of 7 key studies: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), VEST (Vest Prevention of Early Sudden Death Trial), SECURE-PCI (Statins Evaluation in Coronary Procedures and Revascularization), TREAT (Ticagrelor in Patients with ST-Elevation Myocardial Infarction treated with Pharmacological Thrombolysis), POISE (PeriOperative ISchemic Evaluation), SMART-DATE (Safety of 6-Month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome), and CVD-REAL 2 (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors).
|
29753563 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred seventeen patients with STEMI and undergoing pPCI were randomly divided into the sustained nicorandil group (5 mg, three times daily) or the control group (only single nicorandil before PCI).
|
30821716 |
2019 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analysed the proportion of patients with ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention within 90 minutes (primary PCI), the proportion of patients with hip fracture (HF) who underwent surgery within 2 days, and the proportion of women with primary C-section.
|
29584783 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we compared the outcome of conscious survivors of OHCA presenting with ST-elevation myocardial infarction (STEMI) in post-resuscitation electrocardiogram undergoing immediate invasive coronary strategy with randomly selected STEMI patients without preceding OHCA undergoing primary PCI.
|
30244190 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS).
|
31812224 |
2020 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients undergoing p-PCI for STEMI, MEA platelet function observed in coronary arteries was consistent with peripheral artery blood's independently of the antiplatelet drug used.
|
29575927 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
US respondents used TRA less commonly for primary PCI for STEMI than their global counterparts.
|
30456913 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of the CADILLIAC Risk Score can accurately identify patients for safe early discharge after PCI for STEMI.
|
28612413 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We pooled patients with STEMI discharged on prasugrel in 2 prospective registries (Bern PCI Registry [NCT02241291] and SPUM-ACS (Inflammation and Acute Coronary Syndromes) [NCT01000701]) and 1 STEMI trial (COMFORTABLE-AMI (Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction) [NCT00962416]).
|
29654204 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This highlights the persistently dramatic impact of SCA on STEMI and the major importance of PCI in this setting.
|
30608874 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The indication for PCI was chronic stable angina in 46.1% (n=26), non-ST elevation acute coronary syndrome (NSTEACS) in 33.3% (n=18) and ST-elevation myocardial infarction (STEMI) in 18.5% (n=10) of patients.
|
31130523 |
2020 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite primary PCI being the well-established therapy, there are rooms for further research to optimize STEMI outcomes.
|
27846459 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
From 2007 to 2014, 1,525 consecutive patients (79% men, mean age 61 years) who underwent primary percutaneous coronary intervention for STEMI in the INTERSTELLAR (Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute ST-Elevation Myocardial Infarction) cohort were analyzed retrospectively.
|
28214004 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
|
28230176 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, STEMI (OR 1.61; CI 1.52-1.71), performed PCI (OR 2.65; CI 2.42-2.90) and Killip class >2 (OR 1.58; CI 1.36-1.84) favoured referral for CR, while age > 65 years, previous myocardial infarction, cerebrovascular disease or peripheral artery disease had a negative impact on referral for CR.
|
29657032 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to discuss the efficacy and safety of the application of thrombus aspiration catheters during emergency PCI operations for acute ST-elevation myocardial infarction (STEMI) patients with high thrombus load.
|
31547844 |
2019 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in heme-metabolism were characterized in a second STEMI-group by a dual proteomic approach analyzing in-vivo aspirated coronary thrombi at PCI (N=24) and the associated peripheral-blood changes (N=10).
|
28837209 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
During hospitalization, Patients in prior BBs group were more likely to develop decompensated heart failure (9.9% vs. 3.6%, P<0.001), less likely to have STEMI (33.9% vs. 54.4%, P<0.001), and subsequently less PCI (73.2% vs. 81.3%, P=0.002), but higher inpatient mortality (8.8% vs. 4.8%, P=0.009).
|
28747039 |
2017 |